Piper Sandler Downgrades Tango Therapeutics to Neutral, Raises Price Target to $24

Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

0.00

Piper Sandler analyst Kelsey Goodwin downgrades Tango Therapeutics (NASDAQ: TNGX) from Overweight to Neutral and raises the price target from $16 to $24.